Compare
Erasca, Inc. vs Tango Therapeutics, Inc. vs Oncotelic Therapeutics, Inc. vs Harrow, Inc.
| Latest fiscal year | Erasca, Inc. ERAS | Tango Therapeutics, Inc. TNGX | Oncotelic Therapeutics, Inc. OTLC | Harrow, Inc. HROW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $62.38M | n/a | $272.30M |
| Revenue growth (YoY) | n/a | +48.3% | n/a | +36.4% |
| Gross margin | n/a | n/a | n/a | 75.1% |
| Operating margin | n/a | -178.4% | n/a | 11.2% |
| Net margin | n/a | -162.9% | n/a | -1.9% |
| Net income | -$124.55M | -$101.59M | $249.28M | -$5.14M |
| EPS (Diluted) | -$0.44 | -$0.87 | $0.59 | -$0.14 |
| Operating cash flow | -$95.45M | -$138.89M | -$1.38M | $43.86M |
| Free cash flow | -$95.58M | -$139.93M | n/a | $42.98M |
| Cash & equivalents | $73.81M | $112.28M | n/a | $72.93M |
| Total assets | $396.15M | $398.69M | $393.09M | $399.48M |
| Total liabilities | $70.98M | $52.51M | $131.36M | $347.39M |
| Shareholders' equity | $325.17M | $346.18M | $262.76M | $52.45M |
| Return on year-end equity | -38.3% | -29.3% | 94.9% | -9.8% |
| Shares outstanding | 284.16M | 135.94M | 442.60M | 37.23M |
Revenue, most recent five fiscal years
| Fiscal year | Erasca, Inc. | Tango Therapeutics, Inc. | Oncotelic Therapeutics, Inc. | Harrow, Inc. |
|---|---|---|---|---|
| Latest | n/a | $62.38M Ended 2025-12-31 | $70.0K Ended 2023-12-31 | $272.30M Ended 2025-12-31 |
| 1 year earlier | n/a | $42.07M Ended 2024-12-31 | n/a | $199.61M Ended 2024-12-31 |
| 2 years earlier | n/a | $36.53M Ended 2023-12-31 | n/a | $130.19M Ended 2023-12-31 |
| 3 years earlier | n/a | $24.86M Ended 2022-12-31 | $1.74M Ended 2020-12-31 | $88.59M Ended 2022-12-31 |
| 4 years earlier | n/a | $37.04M Ended 2021-12-31 | n/a | $72.48M Ended 2021-12-31 |